^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial

Published date:
01/11/2023
Excerpt:
Here, a phase II trial was performed to explore the safety and efficacy of apatinib combined with camrelizumab in advanced acral melanoma patients as first-line therapy (NCT03955354)….The TMB High rates were 80.0% (4/5) versus 38.4% (5/13) in Re group versus un Re group. According to survival status, a gene set containing TTN, MUC16, VPS13D, ALPK2 and SCUBE1 was established, which was considered positive when at least one gene was altered (Table 3). Patients with gene-set positive showed markedly better PFS and OS than those with gene-set negative in this cohort
DOI:
10.1016/j.ejca.2022.12.027